100 Abbott Park Road
United States - Map
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, pain, fever, inflammation, hypothyroidism, gynecological disorders, intrahepatic cholestasis or depressive symptoms, physiological rhythm of the colon, dyslipidemia, and hypertension, as well as provides anti-infective and influenza vaccines. The companys Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; genomic-based tests; hematology systems and reagents; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents. Its Nutritional Products segment offers pediatric and adult nutritional products comprising various forms of prepared infant and follow-on formula. The companys Vascular Products segment provides coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular disease. Abbott Laboratories also offers blood glucose monitoring meters, test strips, and data management software and accessories for people with diabetes; and medical devices for the eye, including cataract surgery, LASIK surgery, contact lens care products, and dry eye products. The company primarily serves retailers, wholesalers, hospitals, health care facilities, laboratories, physicians offices, and government agencies. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
|Abbott Laboratories’s ISS Governance QuickScore as of May 1, 2013 is 8. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 9; Compensation: 7.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Miles D. White ,
Chairman, Chief Exec. Officer and Chairman of Exec. Committee
|Mr. Thomas C. Freyman ,
Chief Financial Officer and Exec. VP of Fin.
|Mr. John B. Thomas ,
VP of Investor Relations & Public Affairs
|Mr. Hubert L. Allen ,
Exec. VP, Gen. Counsel and Sec.
|Mr. Richard W. Ashley ,
Exec. VP of Corp. Devel.
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|